Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $73.11

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have received an average recommendation of “Hold” from the twenty-one research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $73.11.

A number of equities analysts have recently commented on CRSP shares. Truist Financial lifted their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Chardan Capital dropped their price objective on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Needham & Company LLC restated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, February 12th. Finally, Bank of America lowered their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th.

Insider Transactions at CRISPR Therapeutics

In other news, COO Julianne Bruno sold 1,198 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares in the company, valued at $350,516.46. The trade was a 12.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock worth $1,608,243 over the last quarter. Company insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC raised its position in shares of CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after buying an additional 1,474,439 shares in the last quarter. Capital International Investors raised its position in shares of CRISPR Therapeutics by 10.3% in the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after buying an additional 816,789 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after buying an additional 1,074,238 shares in the last quarter. State Street Corp raised its position in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after buying an additional 599,304 shares in the last quarter. Finally, FMR LLC raised its position in shares of CRISPR Therapeutics by 1.0% in the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after buying an additional 23,075 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $41.94 on Thursday. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $75.91. The business has a 50-day moving average of $43.06 and a two-hundred day moving average of $45.44. The stock has a market capitalization of $3.60 billion, a P/E ratio of -9.60 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, research analysts expect that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.